DOCSLIB.ORG

Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Current Pain and Headache Reports (2019) 23: 37 https://doi.org/10.1007/s11916-019-0774-0 OTHER PAIN (A KAYE AND N VADIVELU, SECTION EDITORS) Membrane Stabilizer Medications in the Treatment of Chronic Neuropathic Pain: a Comprehensive Review Omar Viswanath1,2,3 & Ivan Urits4 & Mark R. Jones4 & Jacqueline M. Peck5 & Justin Kochanski6 & Morgan Hasegawa6 & Best Anyama7 & Alan D. Kaye7 Published online: 1 May 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review Neuropathic pain is often debilitating, severely limiting the daily lives of patients who are affected. Typically, neuropathic pain is difficult to manage and, as a result, leads to progression into a chronic condition that is, in many instances, refractory to medical management. Recent Findings Gabapentinoids, belonging to the calcium channel blocking class of drugs, have shown good efficacy in the management of chronic pain and are thus commonly utilized as first-line therapy. Various sodium channel blocking drugs, belonging to the categories of anticonvulsants and local anesthetics, have demonstrated varying degrees of efficacy in the in the treatment of neurogenic pain. Summary Though there is limited medical literature as to efficacy of any one drug, individualized multimodal therapy can provide significant analgesia to patients with chronic neuropathic pain. Keywords Neuropathic pain . Chronic pain . Ion Channel blockers . Anticonvulsants . Membrane stabilizers Introduction Neuropathic pain, which is a result of nervous system injury or lives of patients who are affected. Frequently, it is difficult to dysfunction, is often debilitating, severely limiting the daily manage and as a result leads to the progression of a chronic condition that is, in many instances, refractory to medical This article is part of the Topical Collection on Other Pain management. Common causes of neuropathic pain include lumbar radiculopathy, diabetic peripheral neuropathy, and * Omar Viswanath postherpetic neuralgia. While antidepressants and several an- [email protected] ticonvulsant medications are widely instituted as first-line therapy, there is a lack of consensus regarding next-line ther- 1 Valley Anesthesiology and Pain Consultants, Envision Physician apy in patients who continue to experience pain. In this re- Services, 645 E. Missouri Avenue, Suite 300, Phoenix, AZ 85012, view, an overview of membrane stabilizing medications is USA presented. These medications have been shown to be effective 2 Department of Anesthesiology, University of Arizona College of in the management of chronic neuropathic pain. Medicine-Phoenix, Phoenix, AZ, USA 3 Department of Anesthesiology, Creighton University School of Medicine, Omaha, NE, USA 4 Beth Israel Deaconess Medical Center, Department of Anesthesia, Sodium Channel Blocking Anticonvulsants Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA, USA The sodium channel blocking class of drugs antiepileptic 5 Department of Anesthesiology, Mt. Sinai Medical Center of Florida, drugs has been proven useful in the treatment of neurogenic Miami Beach, FL, USA pain. Following insult to sensory neurons, there is well- 6 Creighton University School of Medicine – Phoenix Regional documented aberrant expression of sodium channels on pe- Campus, Phoenix, AZ, USA ripheral nerves. It is possible that the antinociceptive proper- 7 Department of Anesthesiology, Louisiana State University Health ties of these agents arise from countering this aberrancy [1]. Science Center, New Orleans, LA, USA Aside from sodium channels, each of the following agents has 37 Page 2 of 9 Curr Pain Headache Rep (2019) 23: 37 unique ranges of activity. Some block calcium channels while Carbamazepine others significantly modulate neurotransmitter levels. These additional, unique profiles may lend insight into best practice Carbamazepine (CBZ) is another antiepileptic compound with a use and limitations of each individual agent in the manage- wide range of molecular targets. The primary mechanism of ment of neuropathic pain [2]. analgesia is thought to be elicited through blockade of specific sodium channels found on peripheral neurons, restricting neuro- nal firing rates. It also inhibits calcium channels and Phenytoin NMDA/AMPA receptors, although only at concentrations signif- icantly higher than the therapeutic range [9]. CBZ has also been Phenytoin (PHT) is a compound derived from barbiturates. It shown to potentiate the analgesic effects of morphine, which is differs molecularly from barbiturates at the C5 position of the an effect consistent with many NMDA antagonizing agents [10]. hydantoin molecule, at which PHT contains two phenyl rings The primary use of CBZ is in the treatment of idiopathic rather than alkyl groups [3]. The mechanism of action has trigeminal neuralgia (ITN), for which it is the first line of treat- been historically understood as a sodium channel modulator, ment. The optimal starting dose is 100 mg PO bid, which should as it blocks virtually all subtypes of voltage-gated sodium be increased 100–200 every week to reach a target dosing of channels (NaV). Recently, PHT has also been shown to antag- 200–400 mg tid [11]. The maximum dose is 1200–1800 mg/ onize voltage-dependent L-type calcium channels and day, although adverse cognitive effects are observed at doses as GABA-A receptors, thus suggesting a more complex mecha- low as 800 mg and 1200 mg in females and males, respectively nism of reducing neuroexcitability and conductance [4]. [12, 13]. HLA genotyping must also be taken into consideration Phenytoin was the first non-sedative compound used to when dosing CBZ. Certain genotypes, such as the HLA-B*15:02 manage epilepsy. Its minimal hypnotic activity is thought to allele, which is common in individuals of Southeastern Asian be attributed to the previously mentioned chemical modifica- descent, are highly associated with life-threatening dermatologic tion. Many patients treated with PHT develop gingival hyper- complications including Stevens–Johnson syndrome and toxic plasia, and this finding sparked research that illustrated epidermal necrolysis [14]. Other adverse effects of CBZ include wound-healing properties and examined its efficacy in treating ataxia, fatigue, drowsiness, memory problems, and impaired diabetic foot ulcers [5]. Other adverse effects include dizzi- sleep, among others. Agranulocytosis is seen in some patients ness, nystagmus, ataxia, gingival hyperplasia, folate deficien- with chronic administration and is thought to be related to sup- cy, and polyneuropathy. As with many antiepileptic com- pression of colony-stimulating factor and impaired neurogenic pounds, drug-induced osteopathy is a potential adverse effect, inflammation [15, 16]. which is thought to be caused by the induction of cytochrome Although there are numerous adverse effects, CBZ appears to metabolism of vitamin D [6]. have a role in the management of neuropathic pain associated The efficacy of intravenous PHT in treating neuropathic with various conditions. Wiffen et al. established a slight efficacy pain was established in a double-blind randomized control of carbamazepine in treating PDN. Patients treated with 600– trial, showing significant pain relief at a dosage of 15 mg/kg 3600 mg/day CBZ reported higher percentages of pain benefit over a 2-h period. This pain relief significantly outlasted the when compared to the control group. While this finding was infusion period and plasma half-life of PHT, supporting future statistically significant, it was regarded as third tier due to small studies to examine the efficacy of topical creams. A series of study sizes and a wide range of doses [17]. A meta-analysis by case reports by Kopsky et al. showed that 10% topical PHT Liu et al. compared interventions for the treatment of neuropathic cream was an effective treatment in reducing neuropathic pain pain in Guillain-Barre syndrome, which included CBZ. A statis- in patients with chronic idiopathic axonal polyneuropathy tically significant reduction in pain scoring and need for rescue (CIAP) and painful diabetic neuropathy (PDN) [7]. In a analgesics was found by the third day of treatment when com- single-blind response study, Kopsky et al. established that pared with the placebo, although a separate randomized control 10% PHT cream, when compared to a placebo, provided sta- trial showed better outcomes associated with gabapentin treat- tistically significant relief in a cohort of 70 patients with neu- ment over CBZ [18]. While it is a mainstay in the treatment of ropathic pain. The mean daily application in this group was ITN, further research is needed to evaluate the use of CBZ in 2.3 g, and no PHT plasma levels were detected in any patient. treating other causes of neuropathic pain. Over 65% of patients achieved a pain reduction of at least 50%, with an average duration of action around 8 h. The mean Oxcarbazepine onset of action was around 15 min, which is significantly shorter than the days to weeks seen in other oral treatments Like CBZ, oxcarbazepine (OXC) is thought to exert its effect [8••]. These findings of significant pain reduction, long dura- through blockade of voltage gated sodium channels. Patel tion of relief, and short onset of action all support the use of et al. showed that OXC reduces spontaneous activity in the topical PHT as an effective treatment for neuropathic pain. ventral posterolateral thalamus in rats with spinal nerve Curr Pain Headache Rep (2019) 23: 37 Page 3 of 9 37 ligations.
Load more

Recommended publications
  • United States July 2016 2 Table of Contents
    Deuterium Labelled Compounds United States July 2016 2 Table of Contents International Distributors 3 Corporate Overview 4 General Information 5 Pricing and Payment 5 Quotations 5 Custom Synthesis 5 Shipping 5 Quality Control 6 Quotations 6 Custom Synthesis 6 Shipping 6 Quality Control 6 Chemical Abstract Service Numbers 6 Handling Hazardous Compounds 6 Our Products are Not Intended for Use in Humans 7 Limited Warranty 7 Packaging Information 7 Alphabetical Listings 8 Stock Clearance 236 Products by Category 242 n-Alkanes 243 α-Amino Acids, N-Acyl α-Amino Acids, N-t-BOC Protected α-Amino Acid 243 and N-FMOC Protected α-Amino Acids Buffers and Reagents for NMR Studies 245 Detergents 245 Environmental Standards 246 Fatty Acids and Fatty Acid Esters 249 Flavours and Fragrances 250 Gases 253 Medical Research Products 254 Nucleic Acid Bases and Nucleosides 255 Pesticides and Pesticide Metabolites 256 Pharmaceutical Standards 257 Polyaromatic Hydrocarbons (PAHs), Alkyl-PAHs, Amino-PAHs, 260 Hydroxy-PAHs and Nitro-PAHs Polychlorinated Biphenyls (PCBs) 260 Spin Labels 261 Steroids 261 3 International Distributors C Beijng Zhenxiang H EQ Laboratories GmbH Australia K Technology Company Graf-von-Seyssel-Str. 10 Rm. 15A01, Changyin Bld. 86199 Augsburg Austria H No. 88, YongDingLu Rd. Germany Beijing 100039 Tel.: (49) 821 71058246 Belgium J China Fax: (49) 821 71058247 Tel.: (86) 10-58896805 [email protected] China C Fax: (86) 10-58896158 www.eqlabs.de Czech Republic H [email protected] Germany, Austria, China Czech Republic, Greece, Denmark I Hungary,
    [Show full text]
  • Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
    toxins Review Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 1 2 3, 4, , Marie-Line Reynaert , Denis Dupoiron , Edouard Yeramian y, Laurent Marsollier * y and 1, , Priscille Brodin * y 1 France Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR8204-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France 2 Institut de Cancérologie de l’Ouest Paul Papin, 15 rue André Boquel-49055 Angers, France 3 Unité de Microbiologie Structurale, Institut Pasteur, CNRS, Univ. Paris, F-75015 Paris, France 4 Equipe ATIP AVENIR, CRCINA, INSERM, Univ. Nantes, Univ. Angers, 4 rue Larrey, F-49933 Angers, France * Correspondence: [email protected] (L.M.); [email protected] (P.B.) These three authors contribute equally to this work. y Received: 29 June 2019; Accepted: 3 September 2019; Published: 4 September 2019 Abstract: Pain currently represents the most common symptom for which medical attention is sought by patients. The available treatments have limited effectiveness and significant side-effects. In addition, most often, the duration of analgesia is short. Today, the handling of pain remains a major challenge. One promising alternative for the discovery of novel potent analgesics is to take inspiration from Mother Nature; in this context, the detailed investigation of the intriguing analgesia implemented in Buruli ulcer, an infectious disease caused by the bacterium Mycobacterium ulcerans and characterized by painless ulcerative lesions, seems particularly promising. More precisely, in this disease, the painless skin ulcers are caused by mycolactone, a polyketide lactone exotoxin. In fact, mycolactone exerts a wide range of effects on the host, besides being responsible for analgesia, as it has been shown notably to modulate the immune response or to provoke apoptosis.
    [Show full text]
  • Neurontin (Gabapentin)
    Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Gabapentin Clinical Criteria Information Included in this Document Neurontin (gabapentin) • Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria • Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules • Logic diagram: a visual depiction of the clinical criteria logic • Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable • References: clinical publications and sources relevant to this clinical criteria Note: Click the hyperlink to navigate directly to that section. Gralise (gabapentin Extended Release) • Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria • Prior authorization criteria logic: a description of how the prior authorization request will be evaluated against the clinical criteria rules • Logic diagram: a visual depiction of the clinical criteria logic • Supporting tables: a collection of information associated with the steps within the criteria (diagnosis codes, procedure codes, and therapy codes); provided when applicable • References: clinical publications and sources relevant to this clinical criteria Note: Click the hyperlink to navigate directly to that section. March 29, 2019 Copyright © 2019 Health Information Designs, LLC 1 Horizant
    [Show full text]
  • K+ Channel Modulators Product ID Product Name Description D3209 Diclofenac Sodium Salt NSAID; COX-1/2 Inhibitor, Potential K+ Channel Modulator
    K+ Channel Modulators Product ID Product Name Description D3209 Diclofenac Sodium Salt NSAID; COX-1/2 inhibitor, potential K+ channel modulator. G4597 18β-Glycyrrhetinic Acid Triterpene glycoside found in Glycyrrhiza; 15-HPGDH inhibitor, hERG and KCNA3/Kv1.3 K+ channel blocker. A4440 Allicin Organosulfur found in garlic, binds DNA; inwardly rectifying K+ channel activator, L-type Ca2+ channel blocker. P6852 Propafenone Hydrochloride β-adrenergic antagonist, Kv1.4 and K2P2 K+ channel blocker. P2817 Phentolamine Hydrochloride ATP-sensitive K+ channel activator, α-adrenergic antagonist. P2818 Phentolamine Methanesulfonate ATP-sensitive K+ channel activator, α-adrenergic antagonist. T7056 Troglitazone Thiazolidinedione; PPARγ agonist, ATP-sensitive K+ channel blocker. G3556 Ginsenoside Rg3 Triterpene saponin found in species of Panax; γ2 GABA-A agonist, Kv7.1 K+ channel activator, α10 nAChR antagonist. P6958 Protopanaxatriol Triterpene sapogenin found in species of Panax; GABA-A/C antagonist, slow-activating delayed rectifier K+ channel blocker. V3355 Vindoline Semi-synthetic vinca alkaloid found in Catharanthus; Kv2.1 K+ channel blocker and H+/K+ ATPase inhibitor. A5037 Amiodarone Hydrochloride Voltage-gated Na+, Ca2+, K+ channel blocker, α/β-adrenergic antagonist, FIASMA. B8262 Bupivacaine Hydrochloride Monohydrate Amino amide; voltage-gated Na+, BK/SK, Kv1, Kv3, TASK-2 K+ channel inhibitor. C0270 Carbamazepine GABA potentiator, voltage-gated Na+ and ATP-sensitive K+ channel blocker. C9711 Cyclovirobuxine D Found in Buxus; hERG K+ channel inhibitor. D5649 Domperidone D2/3 antagonist, hERG K+ channel blocker. G4535 Glimepiride Sulfonylurea; ATP-sensitive K+ channel blocker. G4634 Glipizide Sulfonylurea; ATP-sensitive K+ channel blocker. I5034 Imiquimod Imidazoquinoline nucleoside analog; TLR-7/8 agonist, KCNA1/Kv1.1 and KCNA2/Kv1.2 K+ channel partial agonist, TREK-1/ K2P2 and TRAAK/K2P4 K+ channel blocker.
    [Show full text]
  • Therapeutic Potential of RQ-00311651, a Novel T-Type Ca
    Research Paper Therapeutic potential of RQ-00311651, a novel T-type Ca21 channel blocker, in distinct rodent models for neuropathic and visceral pain Fumiko Sekiguchia, Yuma Kawaraa, Maho Tsubotaa, Eri Kawakamia, Tomoka Ozakia, Yudai Kawaishia, Shiori Tomitaa, Daiki Kanaokaa, Shigeru Yoshidab, Tsuyako Ohkuboc, Atsufumi Kawabataa,* Abstract 21 T-type Ca channels (T channels), particularly Cav3.2 among the 3 isoforms, play a role in neuropathic and visceral pain. We thus characterized the effects of RQ-00311651 (RQ), a novel T-channel blocker, in HEK293 cells transfected with human Cav3.1 or 21 Cav3.2 by electrophysiological and fluorescent Ca signaling assays, and also evaluated the antiallodynic/antihyperalgesic activity of RQ in somatic, visceral, and neuropathic pain models in rodents. RQ-00311651 strongly suppressed T currents when tested at holding potentials of 265 ; 260 mV, but not 280 mV, in the Cav3.1- or Cav3.2-expressing cells. RQ-00311651 also inhibited high K1-induced Ca21 signaling in those cells. In mice, RQ, administered intraperitoneally (i.p.) at 5 to 20 mg/kg or orally at 20 to 40 mg/kg, significantly suppressed the somatic hyperalgesia and visceral pain-like nociceptive behavior/referred hyperalgesia caused by intraplantar and intracolonic administration of NaHS or Na2S, H2S donors, respectively, which involve the enhanced activity of Cav3.2 channels. RQ-00311651, given i.p. at 5 to 20 mg/kg, exhibited antiallodynic or antihyperalgesic activity in rats with spinal nerve injury–induced neuropathy or in rats and mice with paclitaxel-induced neuropathy. Oral and i.p. RQ at 10 to 20 mg/kg also suppressed the visceral nociceptive behavior and/or referred hyperalgesia accompanying cerulein-induced acute pancreatitis and cyclophosphamide-induced cystitis in mice.
    [Show full text]
  • Z944: an Oral T-Type Calcium Channel Modulator for the Treatment of Pain Margaret S
    Z944: An oral T-type calcium channel modulator for the treatment of pain Margaret S. Lee, PhD Ion Channel Retreat 2014, June 25, 2014 T-type Calcium Channels: A Novel Target for Pain and Other CNS Disorders • T-type calcium channels are voltage gated and comprised of three subtypes: Cav3.1, Cav3.2 & Cav3.3 • Expressed in Central and Peripheral Nervous System, including primary afferent, dorsal horn neurons, thalamus and somatosensory cortex • Contribute to neuronal excitability, synaptic excitation, burst firing and action potential trains, and also lower threshold for action potentials Pain Signaling Thalamocortical Connectivity Source: Adapted from Zamponi, et al., Brain Res. Reviews. 2009 Source: Adapted from Park, et al., Frontiers Neural Circuits. 2013 • Rodent neuropathic and IBS pain models exhibit increased • Thalamocortical dysrythmia linked to CNS indications, e.g. T-type current density motor, neuropsychiatric and chronic pain syndromes • Gene knockout or antisense reduces pain in neuropathic, • Mutations in T-type channels are found in rodent and acute and visceral pain models human excitability disorders • T-type channel blockers attenuate neuropathic, • Approved anti-convulsants (e.g. ethosuximide, valproate) inflammatory, acute and visceral pain in animal models target T-type channels © Copyright Neuromed 2 Z944 is a Potent, Selective Blocker of T-type Calcium Channels IC50 (nM) Channel 30% Fold-Selectivity Closed Inactivated (30% Inactivated) CaV3.1(human, exogenous) 50 130 1 CaV3.2 (human, exogenous) 160 540 3.2 CaV3.3 (human, exogenous) 110 260 2.2 N-type (rat, exogenous) 11,000 150,000 220 L-type cardiac calcium (rat CaV1.2) 32,000 -- 640 Cardiac Sodium (human NaV1.5) 100,000 -- 2000 hERG channel (human) 7,800 -- 156 • Displays enhanced potency for the inactivated state across T-type channels • Z944 block of Cav3.2 is more pronounced during high-frequency firing • Z944 has >150-fold selectivity vs.
    [Show full text]
  • Campro Catalog Stable Isotope
    Introduction & Welcome Dear Valued Customer, We are pleased to present to you our Stable Isotopes Catalog which contains more than three thousand (3000) high quality labeled compounds. You will find new additions that are beneficial for your research. Campro Scientific is proud to work together with Isotec, Inc. for the distribution and marketing of their stable isotopes. We have been working with Isotec for more than twenty years and know that their products meet the highest standard. Campro Scientific was founded in 1981 and we provide services to some of the most prestigious universities, research institutes and laboratories throughout Europe. We are a research-oriented company specialized in supporting the requirements of the scientific community. We are the exclusive distributor of some of the world’s leading producers of research chemicals, radioisotopes, stable isotopes and environmental standards. We understand the requirements of our customers, and work every day to fulfill them. In working with us you are guaranteed to receive: - Excellent customer service - High quality products - Dependable service - Efficient distribution The highly educated staff at Campro’s headquarters and sales office is ready to assist you with your questions and product requirements. Feel free to call us at any time. Sincerely, Dr. Ahmad Rajabi General Manager 180/280 = unlabeled 185/285 = 15N labeled 181/281 = double labeled (13C+15N, 13C+D, 15N+18O etc.) 186/286 = 12C labeled 182/282 = d labeled 187/287 = 17O labeled 183/283 = 13C labeleld 188/288 = 18O labeled 184/284 = 16O labeled, 14N labeled 189/289 = Noble Gases Table of Contents Ordering Information.................................................................................................. page 4 - 5 Packaging Information ..............................................................................................
    [Show full text]
  • Zonegran, INN-Zonisamide
    SCIENTIFIC DISCUSSION 1. Introduction Many patients (30 to 40% of the overall population with epilepsy) continue to have seizures in spite of receiving antiepileptic drug (AED) treatment. The prevalence of active epilepsy, 5-10/1000, is one of the highest among serious neurological disorders with more than 50 million people affected worldwide. Two peaks of incidence are observed, in early childhood and among elderly people. Some patients will have life-long epilepsy. International classifications, such as the International League Against Epilepsy (ILAE) classification recognise many epileptic diseases or syndromes and each of them can be expressed clinically by one or several seizure groupings. Partial epilepsies (localisation related) are the more frequent, accounting for more than 60% of the epilepsies, and they include most of the difficult-to-treat patients. In terms of seizure types, partial epilepsies include simple partial seizures (without impairment of consciousness), complex partial seizures (with impairment of consciousness and often more disabling) and secondarily generalized tonic-clonic seizures. The symptoms are a function of the localisation of the site of seizure onset in the brain (epileptogenic zone) and of the propagation pathways of the abnormal discharge. Therapeutic management usually follows a staged approach with newly diagnosed patients starting prophylactic treatment with a single drug, and several alternative drugs may be tried in the event of lack of efficacy or poor tolerability. For patients not responding to several attempts of monotherapy, combinations of antiepileptic drugs are generally employed early in the management process. Uncontrolled epilepsy is associated with cognitive deterioration, psychosocial dysfunction, dependent behaviour, restricted lifestyle, poor quality of life and excess mortality, in particular from sudden unexpected death in epilepsy patients (SUDEP).
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Métrologie De La Douleur Animale Sur Modèles Expérimentaux : Développement Et Validation De Biomarqueurs Neuroprotéomiques
    Université de Montréal Métrologie de la douleur animale sur modèles expérimentaux : développement et validation de biomarqueurs neuroprotéomiques. par Colombe Otis Département de biomédecine vétérinaire Faculté de médecine vétérinaire Thèse présentée à la Faculté de médecine vétérinaire en vue de l’obtention du grade de philosophiæ doctor (Ph. D.) en sciences vétérinaires option pharmacologie Août, 2017 © Colombe Otis, 2017 Résumé La douleur est un phénomène complexe et dynamique comprenant un processus primaire et sensoriel, la nociception, auquel se rajoutent des réactions de défense et d'alarme psychophysiologiques. Ceci conduit au développement d'une véritable mémoire de la douleur, individuelle et modulée (plasticité neuronale) par des expériences précédentes de douleur, incluant entre autres, des phénomènes de sensibilisation nociceptive. Pour bien comprendre les mécanismes de sensibilisation centrale, les modèles animaux mimant les pathologies humaines sont d’une importance primordi ale. Or, pour ce faire, nous avons proposé une série d'approches expérimentales translationnelles par le développement de modèles expérimentaux de douleur bovine, canine et murine afin de caractériser les atteintes du protéome spinal en fonction du niveau de douleur perçu par l'animal et d’identifier le (les) marqueur (s) potentiellement modulé (s) par la sensibilisation nociceptive. À l’aide de la neuroprotéomique, nous avons identifié sur un modèle bovin de douleur viscérale, la protéine transthyrétine (TTR) comme étant sous-exprimée dans le protéome spinal en présence de douleur et ce, vérifié également dans le modèle canin de douleur chronique liée à l’arthrose chirurgicale. Ces résultats suggèrent la possibilité d’entrevoir la TTR comme un biomarqueur potentiel de la douleur chronique. Notre découverte de la relation entre les niveaux spinaux de TTR par neuroprotéomique et l’ hypersensibilité à la douleur dans les modèles bovin et canin soutiennent l’implication de composantes inflammatoires nociceptives et immunitaires.
    [Show full text]
  • Ketamine: an Update for Its Use in Complex Regional Pain Syndrome
    xperim & E en l ta a l ic P in h Bentley et al., Clin Exp Pharmacol 2015, 5:2 l a C r m f Journal of DOI: 10.4172/2161-1459.1000169 o a l c a o n l o r g u y o J ISSN: 2161-1459 Clinical and Experimental Pharmacology Commentry Open Access Ketamine: An Update for Its Use in Complex Regional Pain Syndrome and Major Depressive Disorder William E Bentley*, Michael Sabia, Michael E Goldberg and Irving W Wainer Cooper University Hospital, Camden, New Jersey, United States of America Abstract In recent years, there has been significant research in regard to the efficacy of ketamine in regards to treating Complex Regional Pain Syndrome (CRPS) and Major Depressive Disorder (MDD). Many patients have had substantial symptomatic relief; however, not all patients have had positive results. This has prompted current research with evidence to suggest certain biomarkers exist that would infer which patients will/will not respond to ketamine treatment. Current biomarkers of interest include D-Serine (D-Ser) and magnesium, which will be discussed. Whether or not D-Ser and/or magnesium levels should be checked and possibly dictate therapy is an area of future research. It is also possible that downstream metabolites of ketamine are the key to successful therapy. Keywords: Complex regional pain syndrome; Major Depressive thoughts; and slowing of speech and action. These changes must last a Disorder(MDD); Ketamine minimum of 2 weeks and interfere considerably with work and family relations” [6]. Treatment options include antidepressant medications, Complex Regional Pain Syndrome (CRPS) and Major Depressive cognitive behavioral therapy, and interpersonal therapy.
    [Show full text]
  • Big Pain Assays Aren't a Big Pain with the Raptor Biphenyl LC Column
    Featured Application: 231 Pain Management and Drugs of Abuse Compounds in under 10 Minutes by LC-MS/MS Big Pain Assays Aren’t a Big Pain with the Raptor Biphenyl LC Column • 231 compounds, 40+ isobars, 10 drug classes, 22 ESI- compounds in 10 minutes with 1 column. • A Raptor SPP LC column with time-tested Restek Biphenyl selectivity is the most versatile, multiclass-capable LC column available. • Achieve excellent separation of critical isobars with no tailing peaks. • Run fast and reliable high-throughput LC-MS/MS analyses with increased sensitivity using simple mobile phases. The use of pain management drugs is steadily increasing. As a result, hospital and reference labs are seeing an increase in patient samples that must be screened for a wide variety of pain management drugs to prevent drug abuse and to ensure patient safety and adherence to their medication regimen. Thera- peutic drug monitoring can be challenging due to the low cutoff levels, potential matrix interferences, and isobaric drug compounds. To address these chal- lenges, many drug testing facilities are turning to liquid chromatography coupled with mass spectrometry (LC-MS/MS) for its increased speed, sensitivity, and specificity. As shown in the analysis below, Restek’s Raptor Biphenyl column is ideal for developing successful LC-MS/MS pain medication screening methodologies. With its exceptionally high retention and unique selectivity, 231 multiclass drug compounds and metabolites—including over 40 isobars—can be analyzed in just 10 minutes. In addition, separate panels have been optimized on the Raptor Biphenyl column specifically for opioids, antianxiety drugs, barbiturates, NSAIDs and analgesics, antidepressants, antiepileptics, antipsychotics, hallucinogens, and stimulants for use during confirmation and quantitative analyses.
    [Show full text]